financetom
Business
financetom
/
Business
/
Cirrus Logic Q1 revenue beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cirrus Logic Q1 revenue beats estimates
Aug 5, 2025 1:24 PM

Overview

* Cirrus Logic ( CRUS ) fiscal Q1 revenue of $407.3 mln beats analyst expectations

* Adjusted EPS for fiscal Q1 exceeds analyst estimates, driven by strong product demand

Outlook

* Cirrus Logic ( CRUS ) expects Q2 FY26 revenue between $510 mln and $570 mln

* Company forecasts Q2 FY26 GAAP gross margin of 51% to 53%

* Cirrus Logic ( CRUS ) anticipates Q2 FY26 GAAP R&D and SG&A expenses $153 mln to $159 mln

* Company sees Q2 FY26 non-GAAP operating expenses between $131 mln and $137 mln

Result Drivers

* AMPLIFIER DEMAND - Strong demand for custom boosted amplifier contributed to revenue growth, per CEO John Forsyth

* SMART CODEC - Introduction of 22-nanometer smart codec in smartphones drove sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Beat $407.30 $364.30

Revenue mln mln (7

Analysts

)

Q1 Beat $1.51 $1.1 (7

Adjusted Analysts

EPS )

Q1 EPS $1.14

Q1 $119.50

Adjusted mln

Operatin

g

Expenses

Q1 $141.60

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the semiconductors peer group is "buy"

* Wall Street's median 12-month price target for Cirrus Logic Inc ( CRUS ) is $125.00, about 15.5% above its August 4 closing price of $105.58

* The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Real to Acquire REMAX, Creating a Leading Technology-Enabled Global Real Estate Platform
Real to Acquire REMAX, Creating a Leading Technology-Enabled Global Real Estate Platform
Apr 27, 2026
Unites Real’s AI-powered brokerage platform with REMAX’s iconic real estate brand and global reach to deliver differentiated home buying and selling experience for over 180,000 real estate professionals and their clients across more than 120 countries and territories Combined company would have generated approximately $2.3 billion in annual revenue and $157 million in Adjusted EBITDA before synergies in 2025,...
Space analytics firm HawkEye seeks to raise up to $416 million in US IPO
Space analytics firm HawkEye seeks to raise up to $416 million in US IPO
Apr 27, 2026
April 27 (Reuters) - Space analytics firm HawkEye said on Monday it is seeking to raise up to $416 million in its U.S. initial public offering. ...
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
Apr 27, 2026
$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital, with participation from TCGX, Viking Global Investors, RA Capital Management, and other new and existing investors GAITHERSBURG, Md., April 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. ( ALT ) , a...
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator 
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator 
Apr 27, 2026
Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501...
Copyright 2023-2026 - www.financetom.com All Rights Reserved